
简介:
- 作者: Jinghui Song, Liting Dong, Hanxiao Sun, Nan Luo, Qiang Huang, Kai Li, Xiaowen Shen, Zhe Jiang, Zhicong Lv, Luxin Peng, Meifang Zhang, Kun Wang, Ke Liu, Jiaxu Hong, Chengqi Yi
- 杂志: Molecular Cell
- Doi: https://www.doi.org/10.1016/j.molcel.2022.11.011
- 出版日期: 2023 Jan 5
论文中使用的产品/服务
Quotation shows PackGene:RESTARTv2 expressing AAVs were packaged in PackGene Company.
Research Field:RNA editing
AAV Serotype:AAV6.2; AAVDJ
Animal or cell line strain:HDF and HBE cells were seeded at density of 3 x 10^5 in T75 flask, B-Lymphocytes were seeded at density of 2 x 10^5/ml, and MEFs were seeded into 100 mm culture dishes at a density of 1.5 x 10^5 cells. 24 hours after seeding, cells were transduced by AAV6.2 (EEF2- U1570/EEF2- 2881/PPIB-U272/CFTR-W1282X) at multiplicities of infection 1 x 10^6 (for HDF), 1 x 10^5 (for HBE), and 1 x 10^5 (for B-Lymphocytes). MEFs were transduced by AAVDJ (Idua-W392X) at multiplicities of infection 5 x 10^6. Cell medium were changed 24 hours after transduction. 7 days after transduction, cells were collected.
摘要
Nonsense mutations, accounting for >20% of disease-associated mutations, lead to premature translation termination. Replacing uridine with pseudouridine in stop codons suppresses translation termination, which could be harnessed to mediate readthrough of premature termination codons (PTCs). Here, we present RESTART, a programmable RNA base editor, to revert PTC-induced translation termination in mammalian cells. RESTART utilizes an engineered guide snoRNA (gsnoRNA) and the endogenous H/ACA box snoRNP machinery to achieve precise pseudouridylation. We also identified and optimized gsnoRNA scaffolds to increase the editing efficiency. Unexpectedly, we found that a minor isoform of pseudouridine synthase DKC1, lacking a C-terminal nuclear localization signal, greatly improved the PTC-readthrough efficiency. Although RESTART induced restricted off-target pseudouridylation, they did not change the coding information nor the expression level of off-targets. Finally, RESTART enables robust pseudouridylation in primary cells and achieves functional PTC readthrough in disease-relevant contexts. Collectively, RESTART is a promising RNA-editing tool for research and therapeutics.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
